Sun Pharma Q1 revenue rises 10% as premium mix offsets US generics pressure

The Indian drugmaker's specialty medicines segment drove top-line growth, though management warned of near-term margin headwinds from the Organon acquisition.

{{L:By}} Handelsavisen Newsroom · {{L:Automated}} 2026-08-04 10:36 UTC · 1 {{L:min read}}

Sun Pharmaceutical Industries reported a 10% year-on-year increase in consolidated revenue for the first quarter of fiscal 2027, reaching INR 15,183 crore.

The top-line growth outpaced the company's high single-digit guidance, driven by strong performance in its formulations and innovative medicines segments.

This result underscores the accelerating shift within the Indian pharmaceutical sector toward higher-margin specialty products, a trend that has previously supported significant profit expansion for the group.

Despite the revenue beat, the company's margin profile faces near-term pressure.

Management highlighted that investments in growth initiatives and the integration costs associated with the recent Organon acquisition are weighing on profitability.

While the premium product mix helped cushion the impact of ongoing pricing pressures in the US generics market, the full financial impact of the Organon deal is expected to be more pronounced in subsequent quarters as integration expenses ramp up.